Business
CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies
Oral neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health and slow or prevent disease progression, which would make it the
About this update from Cervomed Inc.
[{"type":"text","content":"Oral neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health and slow or prevent disease progression, which would make it the first disease-modifying treatment in DLB\nPhase 2b RewinD-LB study underway; completion of enrollment planned in 1H 2024, and topline primary efficacy results in expected in 2H 2024\nBOSTON, Oct. 18, 2023 /PRNewswire/ -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for degenerative diseases of the brain, today announced it will present deeper insights highlighting the neflamapimod clinical development program, including findings in phase2a that led to the final Phase 2b study design for the treatment of patients with dementia with Lewy bodies (DLB), in an oral presentation at the 16th Clinical Trials in Alzheimer's Disease (CTAD) conference, being held October 24-27, 2023, in Boston, Massachusetts.\n\n \n \n \n \n \n \n\n \n\"We are pleased to have the opportunity to comprehensively present the findings in phase 2a and discuss the analyses that went into optimizing the Phase 2b study design for the treatment of patients with DLB at the upcoming CTAD conference,\" said John Alam, MD, Chief Executive Officer of CervoMed. \"The presentation will focus on the components of the RewinD-LB study that are intended to increase the probability of success in this trial as we hope to bring a new medicine to patients suffering from neurodegenerative diseases with a high-unmet need.\"\nDetails for the CTAD 2023 Oral Presentation\nTitle: A Phase 2b Clinical Trial of Neflamapimod in Dementia with Lewy Bodies Designed to Confirm the Efficacy Results from Phase 2aDate / Time: Wednesday, October 25, 2023 / 2:50 p.m. ETPresenter: Niels Prins, MD, PhD, Chief Executive Officer of Brain Research Center - AmsterdamSession Title: OC8 - ORAL COMMUNICATIONS\nAbout CervoMed\nCervoMed Inc. (the \"Company\") is a clinical-stage biotechnology company advancing CNS-focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The Company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha (p38a). Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in ...